Filing Flows

Filing Flows › Companies › Niagen Bioscience › Cash flow

Niagen Bioscience cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$2.6M in Q3 2026 · $4.9M over twelve months

Operating cash flow$2.6M
Free cash flow+$2.6M
Cash conversion cycle118 days

Analysis

In Q3 2026, Niagen Bioscience generated $2.6M of operating cash flow. That is $1.1M less than in Q3 2025 ($3.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was $4.9M; the largest uses were buybacks ($5.4M), other financing ($31K), net borrowing (+) / repaid (−) ($2K); besides operations, cash came from other investing ($5.0M), shares issued ($742K); the cash balance rose by $5.2M.

Operating cash flow was $2.6M against net income of −$1.2M. The largest differences: payables +$2.1M, prepaid and other assets −$1.6M, stock-based pay +$1.5M.

Its cash conversion cycle was 118 days (receivables 26 + inventory 188 − payables 96).

Free cash flow

Niagen Bioscience: free cash flow by quarterNiagen Bioscience: free cash flow by quarter$8.6MQ4 2024$7.9MQ1 2025$1.2MQ2 2025$3.7MQ3 2025$679KQ4 2025−$1.2MQ1 2026$2.8MQ2 2026$2.6MQ3 2026
Operating cash flow less capital spending.
Niagen Bioscience: operating cash flow against capital spendingNiagen Bioscience: operating cash flow against capital spendingOperating cash flowCapital spending$8.6M$0Q4 2024$7.9M$0Q1 2025$1.2M$0Q2 2025$3.7M$0Q3 2025$679K$0Q4 2025−$1.2M$0Q1 2026$2.8M$0Q2 2026$2.6M$0Q3 2026
Latest (Q3 2026): Operating cash flow $2.6M, Capital spending $0.

Capital allocation, year by year

Niagen Bioscience: where the cash came from (up) and went (down), by fiscal yearNiagen Bioscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedBuybacksFY2021: Operating cash flow −$24.2MFY2021: Net borrowing −$31KFY2021: Shares issued $36.2M$36.2MFY2021FY2022: Operating cash flow −$15.1MFY2022: Net borrowing −$16KFY2022: Shares issued $7.7M$7.7MFY2022FY2023: Operating cash flow $7.1MFY2023: Net borrowing −$15K$7.1MFY2023FY2024: Operating cash flow $12.1MFY2024: Net borrowing −$11KFY2024: Shares issued $5.4M$17.5MFY2024FY2025: Operating cash flow $13.5MFY2025: Net borrowing −$12KFY2025: Shares issued $7.2MFY2025: Buybacks −$251K$20.8MFY2025
Over these 5 years operating cash flow totalled −$6.5M; the largest uses were operating cash flow ($39.3M) and buybacks ($251K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$69.5M
Debtnone
Net cash$69.5M

Niagen Bioscience funds itself: free cash flow was $4.9M over the last twelve months, with $69.5M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Niagen Bioscience: sources (+) and uses (−) of cash, Q3 2026Niagen Bioscience: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)−$2.8MOperating cash flow$2.6MShares issued$197KOther investing−$52KOther financing−$1K
Niagen Bioscience: sources (+) and uses (−) of cash, TTM to Q3 2026Niagen Bioscience: sources (+) and uses (−) of cash, TTM to Q3 2026Buybacks−$5.4MCash drawn (+) / kept (−)−$5.2MOther investing$5.0MOperating cash flow$4.9MShares issued$742KOther financing−$31KNet borrowing (+) / repaid (−)−$2K

From profit to cash

Niagen Bioscience: net income to operating cash flow, Q3 2026Niagen Bioscience: net income to operating cash flow, Q3 2026Net income−$1.2MDepreciation & amortization$290KStock-based pay$1.5MGains on disposals$3KOther non-cash$12KInventory$116KPayables$2.1MAccrued liabilities$92KDeferred revenue−$272KPrepaid and other assets−$1.6MOperating cash flow$2.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20262618896118
Q2 20263319499128
Q1 20263317494112
Q4 2025251498984
Q3 20252512710150
Q2 20252410710230
Q1 202522827727
Q4 202423836542

Every quarter

QuarterOperating cash flowBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$2.6M——$197K−$2.8M$2.6M
Q2 2026$2.8M−$2.8M—$206K−$191K$2.8M
Q1 2026−$1.2M−$2.4M—$111K−$1.8M−$1.2M
Q4 2025$679K−$251K−$2K$228K−$498K$679K
Q3 2025$3.7M—−$4K$152K−$3.8M$3.7M
Q2 2025$1.2M—−$3K$3.8M−$4.9M$1.2M
Q1 2025$7.9M—−$3K$3.1M−$11.0M$7.9M
Q4 2024$8.6M—−$2K$3.8M−$12.3M$8.6M

Niagen Bioscience: income statement and cash flow

Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%. The chart follows the revenue to costs, profit and cash.

Niagen Bioscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.